Compare EPAM Systems Inc (EPAM) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Eli Lilly And Co — how do they compare? EPAM Systems Inc trades at $113.91 (market cap $5.87B), while Eli Lilly And Co trades at $1,169.35 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 177.2× EPAM Systems Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Eli Lilly And Co for 93 Days on average.
| EPAM | LLY | |
|---|---|---|
Market Cap | $5.87B | $1.04T |
Volume | 847,420 | 3,064,878 |
Sector | Technology | Health |
52-Week High | $221.40 | $1.28K |
52-Week Low | $76.04 | $799.57 |
Typical Hold Time | 37 Days | 93 Days |
Enterprise Value | $5.24B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM trades at $108.32, down 0.91% on the day, with a bearish technical signal but solid fundamentals including a P/E of 15.45 and three consecutive quarterly EPS beats. Revenue grew to $5.46B in 2025, though net income margin compressed to 6.92%. Recent news highlights AI-native revenue growth exceeding 11% and activist investor Engine Capital urging a $750M share buyback.
The stock appears undervalued with a consensus price target of $119, offering ~10% upside, but faces near-term headwinds from slower North American growth and AI disruption to legacy services. Investor sentiment is mixed, balancing strong analyst support (59% buy ratings) against technical weakness and competitive pressures.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
